

## Types of EDL found in the 100 patients with PSPEA

	Patients with SP ≥ 85 (N=21)	Patients with SP <85 (N=79)	Difference
Vascular lesions (haemorrhagic infarct and/or ischemia)	6 (28.6%)	8 (10.1%)	OR: 3.55 (95%CI:1.07- 11.74) <i>p</i> =0.03
Periventricular leukomalacia	3 (14.3%)	7 (8.9%)	OR: 1.08 (95%CI:0.21-5.64) <i>p</i> =1
Malformation of cortical development	2 (9.5%)	3 (3.8%)	OR: 2.67 (95%CI:0.42-17.1) <i>p</i> =0.282
Nonspecific T-2 signal abnormality	0 (0%)	4 (5.1%)	OR: 0.78 (95%CI:0.7-0.87) <i>p</i> =0.576
Mesial temporal atrophy	0 (0%)	3 (3.8%)	OR: 0.78 (95%CI:0.71-0.87) <i>p</i> =1
Tumor	0 (0%)	3 (3.8%)	OR: 0.78 (95%CI:0.71-0.87) <i>p</i> =1
Delayed myelination	0 (0%)	3 (3.8%)	OR: 0.78 (95%CI:0.71-0.87) <i>p</i> =1
Hemispheric atrophy	1 (4.8%)	1 (1.3%)	OR: 3.9 (95%CI:0.23-65.1) <i>p</i> =0.38
Holoprosencephaly	0 (0%)	2 (2.5%)	OR: 0.79 (95%CI:0.71-0.87) <i>p</i> =1
Arachnoid cysts	0 (0%)	2 (2.5%)	OR: 0.79 (95%CI:0.71-0.87) <i>p</i> =1
Agenesis of the corpus callosum	0 (0%)	1 (1.3%)	OR: 0.79 (95%CI:0.71-0.87) <i>p</i> =1
Choroid cyst	0 (0%)	0 (0%)	
Hippocampal asymmetry	0 (0%)	0 (0%)	

**Legend.** OR: Odds ratio. 95%CI: 95% confidence interval. PSPEA: prominent sleep potentiated epileptiform activity. N: number of patients in a particular group. *p*: *p*-value.